These observations and our findings on SRC-1 suggest that pharmacological approaches based on the modulation of leptin sensitivity could represent a potential therapeutic strategy for the treatment of obesity-associated metabolic disease. This evidence concerns the gene NCOA1 and obesity due to melanocortin 4 receptor deficiency.